Kingworld Medicines Group Limited (HKG:1110)
Hong Kong · Delayed Price · Currency is HKD 0.5500
0.00 (0.00%)
Feb 20, 2026, 3:56 PM HKT
Kingworld Medicines Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 939.84 | 1,061 | 1,079 | 957.7 | 847.39 | 745.38 | |
Revenue Growth (YoY) | -10.64% | -1.63% | 12.63% | 13.02% | 13.69% | -23.78% |
Cost of Revenue | 704.62 | 790.64 | 797.99 | 680.07 | 583.79 | 465.23 |
Gross Profit | 235.23 | 270.45 | 280.67 | 277.63 | 263.6 | 280.15 |
Selling, General & Admin | 196.84 | 189.5 | 203.59 | 205.03 | 196.16 | 245.51 |
Research & Development | 17.59 | 17.59 | 18.84 | - | - | - |
Amortization of Goodwill & Intangibles | - | - | - | 13.57 | 13.57 | 13.57 |
Other Operating Expenses | -26.55 | -30 | -20.88 | -22.35 | -17.42 | -45.76 |
Operating Expenses | 188.08 | 177.29 | 201.99 | 197.29 | 192.36 | 214.28 |
Operating Income | 47.15 | 93.16 | 78.68 | 80.34 | 71.24 | 65.87 |
Interest Expense | -12.05 | -13.28 | -11.52 | -12.29 | -11.78 | -15.16 |
Interest & Investment Income | 10.54 | 8.36 | 11.52 | 1.75 | 2.8 | 17.17 |
Earnings From Equity Investments | 18.25 | 19.1 | 8.6 | 7.64 | 8.99 | 12.4 |
Currency Exchange Gain (Loss) | -11.14 | -10.19 | -4.97 | -5.81 | -3.09 | -5.01 |
Other Non Operating Income (Expenses) | -2.91 | -2.91 | - | - | - | -0.37 |
EBT Excluding Unusual Items | 49.83 | 94.23 | 82.31 | 71.63 | 68.16 | 74.91 |
Gain (Loss) on Sale of Investments | 1.63 | -4.25 | 12.94 | 2.89 | 0.47 | -3.36 |
Asset Writedown | 2.09 | 5.16 | -1.36 | -7.3 | 0.8 | -1.6 |
Other Unusual Items | 0.37 | 0.37 | - | 0.36 | - | 0.95 |
Pretax Income | 53.93 | 95.52 | 93.89 | 67.58 | 69.43 | 70.89 |
Income Tax Expense | 13.65 | 21.05 | 32.29 | 24.04 | 18.22 | 20 |
Earnings From Continuing Operations | 40.28 | 74.47 | 61.59 | 43.54 | 51.21 | 50.89 |
Minority Interest in Earnings | -34.85 | -32.91 | -23.5 | -20.8 | -20.89 | -39.17 |
Net Income | 5.43 | 41.56 | 38.1 | 22.74 | 30.32 | 11.72 |
Net Income to Common | 5.43 | 41.56 | 38.1 | 22.74 | 30.32 | 11.72 |
Net Income Growth | -82.53% | 9.09% | 67.52% | -24.99% | 158.78% | -73.02% |
Shares Outstanding (Basic) | 568 | 576 | 592 | 607 | 607 | 614 |
Shares Outstanding (Diluted) | 568 | 576 | 592 | 607 | 607 | 614 |
Shares Change (YoY) | -3.99% | -2.66% | -2.49% | 0.04% | -1.29% | -1.00% |
EPS (Basic) | 0.01 | 0.07 | 0.06 | 0.04 | 0.05 | 0.02 |
EPS (Diluted) | 0.01 | 0.07 | 0.06 | 0.04 | 0.05 | 0.02 |
EPS Growth | -81.81% | 12.06% | 71.79% | -25.02% | 162.17% | -72.75% |
Free Cash Flow | -62.75 | 94.73 | -63.25 | 93.04 | 22.88 | 113.66 |
Free Cash Flow Per Share | -0.11 | 0.16 | -0.11 | 0.15 | 0.04 | 0.18 |
Dividend Per Share | 0.030 | 0.030 | 0.031 | 0.022 | 0.019 | 0.005 |
Dividend Growth | -2.91% | -2.91% | 40.74% | 11.79% | 254.55% | -73.68% |
Gross Margin | 25.03% | 25.49% | 26.02% | 28.99% | 31.11% | 37.59% |
Operating Margin | 5.02% | 8.78% | 7.29% | 8.39% | 8.41% | 8.84% |
Profit Margin | 0.58% | 3.92% | 3.53% | 2.38% | 3.58% | 1.57% |
Free Cash Flow Margin | -6.68% | 8.93% | -5.86% | 9.71% | 2.70% | 15.25% |
EBITDA | 60.81 | 104.64 | 88.52 | 107.39 | 96.46 | 90.2 |
EBITDA Margin | 6.47% | 9.86% | 8.21% | 11.21% | 11.38% | 12.10% |
D&A For EBITDA | 13.66 | 11.49 | 9.84 | 27.05 | 25.22 | 24.32 |
EBIT | 47.15 | 93.16 | 78.68 | 80.34 | 71.24 | 65.87 |
EBIT Margin | 5.02% | 8.78% | 7.29% | 8.39% | 8.41% | 8.84% |
Effective Tax Rate | 25.30% | 22.04% | 34.39% | 35.57% | 26.25% | 28.21% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.